In 2023, Germany led in global antihypertensive medicine sales at $357.2 million, despite a slight decrease of 0.89%. Italy and Australia followed, with sales of $177.4 million and $162.2 million, respectively. Notably, Australia experienced a significant growth of 13.35%. Conversely, countries like Chile and Italy saw declines of 5.3% and 3.31%, respectively. Smaller markets such as Iceland and Slovenia showed impressive growth, with percentage increases of 9.86% and 4.87%. The average compound annual growth rate (CAGR) over the last five years indicates a robust yet varied landscape across these nations.
Future trends to watch include the increasing role of generic medicines, innovative delivery systems, and a growing emphasis on personalized medicine. Additionally, emerging markets may witness heightened sales growth due to improved healthcare access and rising awareness of hypertension management.
Top countries in Antihypertensive Medicine Sales by Country
| # | 10 Countries | Million US Dollars | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Germany | 357.2 | 2023 | +0.056% | -0.89% | View data |
| 2 | 2 Italy | 177.4 | 2023 | +1.03% | -3.31% | View data |
| 3 | 3 Australia | 162.2 | 2023 | +10.79% | +13.35% | View data |
| 4 | 4 Austria | 56.8 | 2023 | +0.53% | +1.05% | View data |
| 5 | 5 Sweden | 32.6 | 2023 | +7.95% | +5.04% | View data |
| 6 | 6 Chile | 8.3 | 2023 | +3.75% | -5.3% | View data |
| 7 | 7 Slovenia | 5.2 | 2023 | 0% | +4.87% | View data |
| 8 | 8 Costa Rica | 1.5 | 2023 | +15.38% | +4.56% | View data |
| 9 | 9 Estonia | 1.4 | 2023 | 0% | +3.13% | View data |
| 10 | 10 Iceland | 0.8 | 2023 | 0% | +9.86% | View data |
